e-ESO Podcasts

Primary endocrine resistant in recurrent locoregional only Breast cancer (role of endocrine therapy) 22.09.2022 12:28 ↓

Expert: Stefan Aebi, Lucerne Cantonal Hospital, Lucerne, CH

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? 15.09.2022 6:52 ↓

Expert: Marwan Tolba, McGill University, Montreal, Canada

The use of Lutetium PSMA as treatment in mCRPC – in what sequence and how to best select patients 08.09.2022 17:48 ↓

Experts: Ursula Vogl, Cantonal Hospital of Southern Switzerland, Bellinzona, Switzerland Niklaus Schaefer, University Hospital of Canton Vaud, Lausanne, Switzerland

Use of Medical Cannabis in Oncology. Knowledges and attitudes among oncologist and patient. 01.09.2022 12:08 ↓

Experts: Raffaele Giusti, Sant’Andrea Hospital, Rome, Italy Giampiero Porzio, Associazione Tumori Toscana, Florence, Italy

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? 27.07.2022 9:28 ↓

Expert: Luiza Weis, Cancer Institute of Brasilia - ICB, Brasília, Brazil

Anal cancer in older adults: A Young International Society of Geriatric Oncology review paper 21.07.2022 5:53 ↓

Expert: Dr Bertha Alejandra Martinez-Cannon, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

Cardio-Oncology 14.07.2022 11:22 ↓

Experts: Yusuf Ziya Sener , Hacettepe University Faculty of Medicine, Ankara, Turkey Evandro de Azambuja , Br. E.A.S.T. Data Centre, Jules Bordet Institute, Brussels, Belgium

Non RMS sarcoma in children: 5 tricky questions to an expert 07.07.2022 17:06 ↓

Expert: Daniel Orbach, Curie Institute, Paris, France

Recent advances in the management of stage 3 lung cancer 30.06.2022 7:44 ↓

Expert: Andrea Riccardo Filippi, Policlinico S. Matteo IRCCS Foundation, Pavia, Italy

Management of locally advanced/metastatic Colon cancer especially on the safety of Avastin in patient who receive Colostomy fashioning 23.06.2022 20:03 ↓

Expert: Katia Roque Perez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

Metabolic disorders and the risk of cholangiocarcinoma 16.06.2022 10:58 ↓

Expert: Michele Ghidini, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Combining the past and present to advance immuno-radiotherapy of cancer 09.06.2022 9:16 ↓

Expert: Ioannis Koukourakis, Aretaieio University Hospital, Athens, Greece

Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors 01.06.2022 12:53 ↓

Expert: Mohammed Ezzi, University of Nairobi, Nairobi, Kenya

Chemotherapy in pancreatic ductal adenocarcinoma: when cytoreduction is the aim. A systematic review and meta-analysis 26.05.2022 5:32 ↓

Expert: Mónica Isabel Meneses Medina, National Institute of Health Sciences and Nutrition “Salvador Zubirán”, Mexico City, Mexico

Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies 19.05.2022 5:17 ↓

Expert: Jemma Arakelyan, City University of Hong Kong, Hong Kong, China

Sex and gender differences in oncology 05.05.2022 14:38 ↓

Expert: Berna Özdemir, Inselspital, University Hospital Bern, Bern, CH

Women in medicine and in Oncology 28.04.2022 10:57 ↓

Expert: Malgorzata Osmola, University Clinical Centre Medical University of Warsaw, Warsaw, Poland

Breast Cancer in the Elderly 21.04.2022 16:14 ↓

Expert: Laura Biganzoli, Prato Hospital, Prato, Italy

Summary/Review - Reporting Guidelines - STARD 2015 14.04.2022 7:18 ↓

Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy

Choosing between an academic and clinical career 07.04.2022 28:24 ↓

Experts: Berardino De Bari , Radiation Oncologist, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland Ilaria Colombo , Medical oncologist, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

Ketogenic diets in breast cancer patients 31.03.2022 13:54 ↓

Expert: Diana Artene, Sc Medikin SRL, Bucharest, Romania Questions: What is obesity impact on breast cancer treatment efficacy and side effects What is a ketogenic diet? Do we have safety and efficacy data for recommending ketogenic diets to breast cancer patients? Are there metabolic differences between different immunohistochemical breast cancer subtypes? What is the take home message for our br...

Summary/Review - Reporting Guidelines - MOOSE 2020 24.03.2022 7:58 ↓

Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy

Summary/Review - ESTRO-ACROP consensus statements on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer 10.03.2022 5:12 ↓

Expert: Icro Meattini, Florence University, Florence, Italy

Immunotherapy rechallenge in NSCLC 03.03.2022 7:12 ↓

Expert: Alessandra Curioni-Fontecedro , University Hospital Zurich, Zurich, Switzerland Questions: 1.What's the accurate definition of immunotherapy rechallenge? 2.When we could rechallenge with immunotherapy after failure of previous I.O based therapy ? 3.There is any biomarkers to guide us in I.O rechallenge? 4.Which type of I..O could be used after failure of previous I.O? 5.what is the current...

ESO’s career development programme 24.02.2022 8:52 ↓

Expert: Nicholas Pavlidis, University of Ioannina, Ioannina, Greece